Headquarters: Tokyo, Japan
Founded: 2023 (University of Tokyo spin-out)
Focus: Brain-targeted nanopharmaceuticals for neurodegenerative diseases
Website: https://www.tni-u-tokyo.jp
Headquarters: Tokyo, Japan
Founded: 2023 (University of Tokyo spin-out)
Focus: Brain-targeted nanopharmaceuticals for neurodegenerative diseases
Website: https://www.tni-u-tokyo.jp
Overview
Mermaid diagram (expand to render)
Tokyo NeuroInnovation (TNI) is a University of Tokyo spin-out company developing next-generation brain-targeted drug delivery systems using proprietary nanoparticle technology. The company's core innovation addresses the most significant bottleneck in neurodegeneration drug development: delivering therapeutic compounds across the blood-brain barrier (BBB)[@tni2024].
The blood-brain barrier is a tightly regulated interface between the circulatory system and the central nervous system that prevents most molecules from entering the brain. While this protective function is essential for neural health, it has historically prevented otherwise promising therapeutics from reaching their targets in the brain. Tokyo NeuroInnovation has developed a family of brain-targeting nanoparticles that exploit endogenous receptor-mediated transcytosis pathways to achieve efficient and safe brain penetration["@bbb_nanotech"].
Scientific Foundation
Blood-Brain Barrier Biology
The blood-brain barrier consists of a continuous layer of brain endothelial cells surrounded by pericytes and astrocyte end-feet. Tight junctions between endothelial cells restrict paracellular diffusion, while efflux transporters (P-glycoprotein, BCRP, MRP family members) actively pump lipophilic molecules back into the bloodstream. Together, these features restrict brain penetration to small molecules (<400 Da) that are not substrates for efflux transporters[@transferrin_brain].
Receptor-Mediated Transcytosis
Tokyo NeuroInnovation's technology exploits receptor-mediated transcytosis (RMT), a natural mechanism used by essential molecules like transferrin, insulin, and LDL to cross the BBB[@transferrin_brain]. By decorating nanoparticles with ligands for BBB receptors, the company enables transport across the barrier through vesicular trafficking pathways.
Key receptors exploited by TNI's platform:
Transferrin receptor (TfR1): Abundantly expressed on brain endothelial cells; high affinity for iron-loaded transferrin[@transferrin_brain]
Low-density lipoprotein receptor (LDLR): Accepts various apolipoprotein-decorated particles[@lrp1_nanov]
LRP1 (LDL receptor-related protein 1): Endocytoses ligands and undergoes transcytosis across endothelial cells[@lrp1_nanov]
ApoE receptor: Naturally transports lipid-containing particles across the BBB
Nanoparticle Platform
TNI's nanoparticles are engineered from biocompatible polymers and surface-functionalized with brain-targeting ligands. The platform features:
Core nanocarrier: 20-80 nm biodegradable polymer particles loaded with drug payload
Surface engineering: Dense display of targeting ligands for selective BBB interaction
Modular design: Swap targeting ligands and payloads for different disease applications
Tunable release: Controlled drug release kinetics for sustained therapeutic exposure[@nanocarrier_design]
Pipeline
TN-401 (Lead Program)
Target: Delivery of PGC-1alpha activators to brain
Stage: Preclinical (formulation optimization)
Indication: Parkinson's disease (mitochondrial dysfunction targeting)
TN-401 encapsulates mitochondrial protective compounds in brain-targeted nanoparticles for enhanced CNS delivery. The targeting approach increases brain accumulation by 10-20 fold compared to free drug, enabling oral dosing with adequate brain exposure[@angiopep_brain].
Large molecules like monoclonal antibodies do not cross the BBB efficiently. TN-402 uses TNI's nanoparticle platform to deliver anti-tau antibodies across the barrier, potentially enabling antibody-based therapies for Alzheimer's disease to achieve therapeutic brain concentrations with manageable dosing regimens.
Platform Capabilities
Tokyo NeuroInnovation offers:
BBB transport prediction: In silico models for nanoparticle brain penetration
Formulation development: Nanoparticle manufacturing under GMP conditions
Biodistribution analysis: Quantitative imaging of brain vs. peripheral exposure
Custom delivery services: Partner collaboration on specific targets
Connection to NeuroWiki Topics
TNI's platform intersects with multiple NeuroWiki mechanisms:
[Mitochondrial dysfunction in Parkinson's disease](/mechanisms/mitochondrial-dysfunction-parkinsons)
[Focused ultrasound for BBB opening](/therapeutics/focused-ultrasound-bbb-opening)
[ApoE and lipid metabolism in Alzheimer's disease](/mechanisms/apoe-lipid-metabolism)